Join
Live feed
·
PRReleasevia Quantisnow
LAVA Therapeutics N.V. logo

LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
LVTX· LAVA Therapeutics N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LVTX (LAVA Therapeutics N.V.) and more on Quantisnow.